C
Carolyn Owen
Researcher at Tom Baker Cancer Centre
Publications - 132
Citations - 7489
Carolyn Owen is an academic researcher from Tom Baker Cancer Centre. The author has contributed to research in topics: Chronic lymphocytic leukemia & Ibrutinib. The author has an hindex of 27, co-authored 102 publications receiving 5670 citations. Previous affiliations of Carolyn Owen include Charles University in Prague & University of Calgary.
Papers
More filters
Journal ArticleDOI
Obinutuzumab plus Chlorambucil in Patients with CLL and Coexisting Conditions
Valentin Goede,Kirsten Fischer,Raymonde Busch,Anja Engelke,Barbara Eichhorst,Clemens M. Wendtner,Tatiana Chagorova,Javier de la Serna,Marie-Sarah Dilhuydy,Thomas Illmer,Stephen Opat,Carolyn Owen,Olga Samoylova,Karl-Anton Kreuzer,Stephan Stilgenbauer,Hartmut Döhner,Anton W. Langerak,Matthias Ritgen,Michael Kneba,Elina Asikanius,Kathryn Humphrey,Michael Wenger,Michael Hallek +22 more
TL;DR: Combining an anti-CD20 antibody with chemotherapy improved outcomes in patients with CLL and coexisting conditions, and obinutuzumab was superior to rituximab when each was combined with chlorambucil.
Journal ArticleDOI
Ibrutinib as initial therapy for patients with chronic lymphocytic leukemia
Jan A. Burger,Alessandra Tedeschi,Paul M. Barr,Tadeusz Robak,Carolyn Owen,Paolo Ghia,Osnat Bairey,Peter Hillmen,Nancy L. Bartlett,Jianyong Li,David Simpson,Sebastian Grosicki,Stephen Devereux,Helen McCarthy,Steven Coutre,Hang Quach,Gianluca Gaidano,Zvenyslava Maslyak,Don A. Stevens,Ann Janssens,Fritz Offner,Jiří Mayer,Michael O'Dwyer,Andrzej Hellmann,Anna Schuh,Tanya Siddiqi,Aaron Polliack,Constantine S. Tam,Deepali Suri,Mei Cheng,Fong Clow,Lori Styles,Danelle F. James,Thomas J. Kipps +33 more
TL;DR: Ibrutinib was superior to chlorambucil in previously untreated patients with CLL or small lymphocytic lymphoma, as assessed by progression-free survival, overall survival, response rate, and improvement in hematologic variables.
Journal ArticleDOI
Ibrutinib Regimens versus Chemoimmunotherapy in Older Patients with Untreated CLL
Jennifer A. Woyach,Amy S. Ruppert,Nyla A. Heerema,Weiqiang Zhao,Allison M Booth,Wei Ding,Nancy L. Bartlett,Danielle M. Brander,Paul M. Barr,Kerry A. Rogers,Sameer A. Parikh,Steven Coutre,Arti Hurria,Jennifer R. Brown,Gerard Lozanski,James S. Blachly,Hatice Gulcin Ozer,Brittny Major-Elechi,Briant Fruth,Sreenivasa Nattam,Richard A. Larson,Harry P. Erba,Mark R. Litzow,Carolyn Owen,Charles S. Kuzma,Jeremy S. Abramson,Richard F. Little,Scott E. Smith,Richard Stone,Sumithra J. Mandrekar,John C. Byrd +30 more
TL;DR: Among older patients with untreated CLL, treatment with ibrutinib was superior to treatment with bendamustine plus rituximab with regard to progression‐free survival, and there was no significant difference among the three treatment groups with respect to overall survival.
Journal ArticleDOI
Venetoclax–Rituximab in Relapsed or Refractory Chronic Lymphocytic Leukemia
John F. Seymour,Thomas J. Kipps,Barbara Eichhorst,Peter Hillmen,James D’Rozario,Sarit Assouline,Carolyn Owen,John F. Gerecitano,Tadeusz Robak,Javier de la Serna,Ulrich Jaeger,Guillaume Cartron,Marco Montillo,Rod A. Humerickhouse,Elizabeth Punnoose,Yan Li,Michelle Boyer,Kathryn Humphrey,Mehrdad Mobasher,Arnon P. Kater +19 more
TL;DR: Among patients with relapsed or refractory chronic lymphocytic leukemia, venetoclax plus rituximab resulted in significantly higher rates of progression‐free survival than bendamustine plus r ituximac, and the benefit was maintained across all clinical and biologic subgroups.
Journal ArticleDOI
Obinutuzumab for the First-Line Treatment of Follicular Lymphoma
Robert Marcus,Andrew Davies,Kiyoshi Ando,W. Klapper,Stephen Opat,Carolyn Owen,Elizabeth H Phillips,Randeep Sangha,Rudolf Schlag,John F. Seymour,William Townsend,Marek Trněný,Michael Wenger,Günter Fingerle-Rowson,Kaspar Rufibach,Tom Moore,Michael Herold,Wolfgang Hiddemann +17 more
TL;DR: Obinutuzumab‐based immunochemotherapy and maintenance therapy resulted in longer progression‐free survival than rituximab‐ based therapy.